Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
about
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designThe HIV vaccine sagaA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesMutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complexSequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesRecent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate.B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.A method for identification of HIV gp140 binding memory B cells in human blood.Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery.A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoproteinEffect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primatesCoexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controllerAnti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityImmunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.Fab crystallization and preliminary X-ray analysis of NC-1, an anti-HIV-1 antibody that recognizes the six-helix bundle core of gp41.Comparing antigenicity and immunogenicity of engineered gp120.Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.Structure-based vaccine design in HIV: blind men and the elephant?Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.Receptor binding domain based HIV vaccines.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.
P2860
Q24679395-B5BEF867-55ED-4795-8879-4578A493F9D4Q24805100-D5668A6A-1710-495A-80A8-F9A8D60F5C81Q27302081-D92BEC1B-CBFA-448C-BE81-F35103B84387Q27489000-F5E68BF5-2A1C-4ED9-8F5F-FF7C6DE71BA1Q27637675-23699F26-4D75-440B-AD9E-0C45F069CFC1Q27670829-B59BE1F4-0EC5-4CA5-BC8B-33C7B8F2CB11Q27674878-C9A00C46-8D9D-4D9B-8828-62B5378331F6Q28299280-BE4DF718-982F-4851-8B8D-EC744A16B90EQ28743092-CFA847D0-D10E-4809-AF40-A2D0EE4AC9E0Q29619015-09CBB2D3-381B-46F3-83CA-B93A66C5BACDQ30353580-808A9CDD-3186-4D4B-AF9C-4FB5FA3E0377Q30360326-A0773FC6-8784-447F-AE51-17E3DF6027D0Q30490942-78374E68-92B8-4C1D-A63D-CC6AB7A65313Q30894431-CA85DB8E-890E-44B5-9F28-5B6ECCD77508Q33373664-A5DDC708-C405-4DB5-9451-4131F0E4F974Q33394829-811AA6BF-0F5F-4EC5-B79B-2399FD109F98Q33413784-3333013E-79F9-4C87-9213-75189253C06AQ33522232-E86119BB-BBB1-45A0-AB77-FB3C92F5072FQ33571825-31C40512-6C6B-4ED4-9B28-4FB02A6930F2Q33614605-DE350A6D-27EF-46B0-A358-9F8C524DE1CEQ33786447-8B5781BB-6735-4C80-BF44-CAC5E4A81056Q33826951-727307F8-36F3-4615-8A40-A000C6BECFBDQ33835295-4625594E-694D-4189-9410-6751D8C64711Q33836042-4C3EB779-27F7-49AA-96FA-988341EFCF4DQ33911809-A6A6D9B6-FE99-43C5-AB42-21BCC9A3DCACQ33930424-A671378F-63BA-4E5D-8225-123EB09B6665Q33967511-89800316-FC7C-4030-A8C9-736283133265Q33984309-EFE8A62C-14DC-4637-B638-241EE35E2315Q34096530-E846B34E-ACF2-484E-B112-D9021A8627E8Q34332284-58482DA2-387E-4EAB-9496-4B3A61310864Q34332728-9B977B9E-BF96-4C75-ABB3-BAB39DF8D3D2Q34334135-C726C163-C1F3-4002-A4A5-8F6F2994F860Q34361680-14C9F771-1958-424D-B9F6-55A83915C439Q34363707-8AE03456-45EF-414B-A201-6E9E8825B9B5Q34706815-4D056977-ADEF-4172-B8C5-84A6DDD29B48Q34948645-F8D0B5F9-154A-4B05-989C-79DE26D8E9DEQ34987048-A4FE2B1A-7457-44DE-B717-F02EF0B2F21BQ34999293-725B6ECE-6C6C-4056-91BB-F098F2E39785Q35033862-2C82E5A6-91AF-4F91-9F38-0731A9417F89Q35110976-8B971067-AA2F-426B-B2FE-EBBD75BB63C8
P2860
Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Characterization of stable, so ...... type 1 envelope glycoproteins.
@ast
Characterization of stable, so ...... type 1 envelope glycoproteins.
@en
type
label
Characterization of stable, so ...... type 1 envelope glycoproteins.
@ast
Characterization of stable, so ...... type 1 envelope glycoproteins.
@en
prefLabel
Characterization of stable, so ...... type 1 envelope glycoproteins.
@ast
Characterization of stable, so ...... type 1 envelope glycoproteins.
@en
P2093
P2860
P1433
P1476
Characterization of stable, so ...... type 1 envelope glycoproteins.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.12.5716-5725.2000
P577
2000-06-01T00:00:00Z